Estradiol regulates MBOAT1-mediated ferroptosis and participates in the progression of endometriosis

other OA: bronze public-domain-us
AI-generated summary by claude@2026-07, 2026-07-20

Estradiol regulates MBOAT1 expression to modulate ferroptosis, which plays a role in endometriosis progression, as demonstrated by altered ferroptosis resistance and lesion size in mouse models.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text

This paper examined whether estradiol regulates ferroptosis in endometriosis through membrane-bound O-acyltransferase domain-containing 1 (MBOAT1), assessing estrogen receptor (ESR1/ESR2) and MBOAT1 expression in human endometrium and primary endometrial stromal cells (ESCs). In ectopic ESCs, the authors found increased ESR1, ESR2, and MBOAT1 expression alongside resistance to ferroptosis and reduced sensitivity to RSL3-induced ferroptosis, while estradiol up-regulated MBOAT1 and alleviated RSL3-induced ferroptosis in normal ESCs; conversely, the estrogen receptor inhibitor fulvestrant reduced MBOAT1 and increased ferroptosis in ectopic ESCs. In an endometriosis mouse model, fulvestrant treatment for 2 weeks decreased ectopic lesion number and size by promoting ferroptosis. This paper is centrally about endometriosis — specifically, it links estradiol/MBOAT1 regulation of ferroptosis to endometriosis progression.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

AIM: Endometriosis is an estrogen-dependent disease with unclear pathogenesis. Recent evidence suggests that ferroptosis plays an important role in the development of endometriosis. In this study, we aimed to explore whether membrane-bound O-acyltransferase domain-containing 1 (MBOAT1) is a key factor by which estradiol (E2) regulates ferroptosis in endometriosis. METHODS: The expression of estrogen receptors (ESR1 and ESR2) and MBOAT1 was examined by western blotting in endometrium and primary endometrial stromal cells (ESCs). We measured iron content, MDA, and GSH levels using corresponding assay kits and assessed the level of ROS by flow cytometry to evaluate ferroptosis. We treated primary ESCs and human ESCs (T HESCs) with or without RSL3, E2, and an estrogen receptor inhibitor, fulvestrant (Ful), to verify the regulatory relationship between E2 and ferroptosis. In addition, endometriosis model mice were constructed and treated with an intraperitoneal injection of 5 mg/kg Ful once a day for 2 weeks. RESULTS: Ectopic ESCs (EESCs) showed increased expression of ESR1, ESR2, and MBOAT1. Meanwhile, EESCs demonstrated resistance to ferroptosis compared with normal ESCs (NESCs). Compared with NESCs, EESCs showed significant resistance to RSL3-induced ferroptosis. E2 could up-regulate the expression of MBOAT1 and alleviate RSL3-induced ferroptosis in NESCs, while Ful could down-regulate the expression of MBOAT1 and accelerate RSL3-induced ferroptosis in EESCs. Furthermore, Ful treatment significantly decreased the number and size of ectopic lesions in endometriosis mice by promoting ferroptosis. CONCLUSION: E2 affected ferroptosis by regulating the expression of MBOAT1 and further participated in the progression of endometriosis.
Full text 2,170 characters · extracted from oa-html · 4 sections · click to expand

Abstract

Aim Endometriosis is an estrogen-dependent disease with unclear pathogenesis. Recent evidence suggests that ferroptosis plays an important role in the development of endometriosis. In this study, we aimed to explore whether membrane-bound O-acyltransferase domain-containing 1 (MBOAT1) is a key factor by which estradiol (E2) regulates ferroptosis in endometriosis.

Methods

The expression of estrogen receptors (ESR1 and ESR2) and MBOAT1 was examined by western blotting in endometrium and primary endometrial stromal cells (ESCs). We measured iron content, MDA, and GSH levels using corresponding assay kits and assessed the level of ROS by flow cytometry to evaluate ferroptosis. We treated primary ESCs and human ESCs (T HESCs) with or without RSL3, E2, and an estrogen receptor inhibitor, fulvestrant (Ful), to verify the regulatory relationship between E2 and ferroptosis. In addition, endometriosis model mice were constructed and treated with an intraperitoneal injection of 5 mg/kg Ful once a day for 2 weeks.

Results

Ectopic ESCs (EESCs) showed increased expression of ESR1, ESR2, and MBOAT1. Meanwhile, EESCs demonstrated resistance to ferroptosis compared with normal ESCs (NESCs). Compared with NESCs, EESCs showed significant resistance to RSL3-induced ferroptosis. E2 could up-regulate the expression of MBOAT1 and alleviate RSL3-induced ferroptosis in NESCs, while Ful could down-regulate the expression of MBOAT1 and accelerate RSL3-induced ferroptosis in EESCs. Furthermore, Ful treatment significantly decreased the number and size of ectopic lesions in endometriosis mice by promoting ferroptosis.

Conclusion

E2 affected ferroptosis by regulating the expression of MBOAT1 and further participated in the progression of endometriosis. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. DATA AVAILABILITY STATEMENT Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-07-25T06:15:30.875455+00:00
pubmed
last seen: 2026-07-25T06:10:26.848937+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine